New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 23, 2012
13:15 EDTMAPP, WMT, ALU, RIMM, OCZ, BAXOn The Fly: Closing Wrap
Stocks on Wall Street were higher during the post-holiday short session, with each of the major averages adding over 1%. Following an initial move higher in the first hour after the bell, aided by some encouraging economic data from abroad, the indices drifted higher for the remainder of the day and closed at their highs... ECONOMIC EVENTS: In the U.S., no major economic data was released, however, in Europe, separate reports showed business confidence increased in November in both Germany and France. Also, in China, HSBC's Manufacturing Purchasing Managers' Index increased to 50.4, indicating expansion... COMPANY NEWS: Wal-Mart (WMT) announced had its "best ever Black Friday events" in spite of some scattered strikes by workers and shares advanced $1.31, or 1.90%, to $70.20... Research in Motion (RIMM) shares benefited a day after National Bank raised it price target on the stock to $15 from $12. The firm said in a note to investors yesterday that RIM's new management team is executing by maintaining the BlackBerry subscriber base and U.S. listed shares rose $1.40, or 13.65%, to $11.66 in their first day of trading following the bullish write-up... Shares of Baxter (BAX) moved up $2.69, or 4.07%, to $68.81 after The Wall Street Journal said the company is in talks to buy medical-equipment maker Gambro for about $4B to round out its kidney-dialysis business... MAJOR MOVERS: Among the notable gainers were Alcatel-Lucent (ALU), up 10c, or 10.00%, to $1.10 after Bloomberg said the company is in talks with Goldman Sachs (GS) on a loan to strengthen its balance sheet, and MAP Pharmaceuticals (MAPP), up $2.60, or 20.28%, to $15.42 after the company announced that the FDA accepted its Levadex resubmission with a six-month review. Among the noteworthy losers was OCZ Technology (OCZ), which fell 3c, or 2.52%, to $1.16 following its disclosure of a SEC inquiry... INDICES: The Dow was up 172.79, or 1.35%, to 13,009.68; the Nasdaq was up 40.30, or 1.38%, to 2,966.85; and the S&P 500 was up 18.12, or 1.30%, to 1,409.15.
News For RIMM;WMT;BAX;ALU;MAPP;OCZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:01 EDTWMTWal-Mart volatility flat into U.S. strategic update
Subscribe for More Information
09:02 EDTWMTSamsung Galaxy S6, S6 edge to be available in U.S. beginning April 10
Samsung Electronics America (SSNLF) announced the Galaxy S 6 and Galaxy S 6 edge will be available in the U.S. beginning April 10, with pre-orders starting March 27. In the U.S., the Galaxy S 6 and Galaxy S 6 edge will be available in Black Sapphire, White Pearl and Gold Platinum -- in 32GB, 64GB and 128GB2 memory options. AT&T (T), Sprint (S), T-Mobile (TMUS), U.S. Cellular (USM) and Verizon Wireless (VZ) will carry both the Galaxy S 6 and Galaxy S 6 edge, while Boost Mobile, Cricket Wireless and MetroPCS will carry the Galaxy S 6. Samsung Experience Shops at Best Buy (BBY), as well as Amazon.com (AMZN), Costco Wholesale (COST), Samís Club (WMT), Target (TGT) and Walmart will also carry the Galaxy S 6 and Galaxy S 6 edge. Carriers and retailers will confirm specific pricing and availability.
08:08 EDTWMTStratasys' MakerBot expands 3D printer sales to Sam's Club locations
MakerBot (SSYS) says it recently started selling the MakerBot Replicator Mini Compact 3D Printer at more than 300 Samís Club (WMT) retail locations across the United States.
07:25 EDTALUThe Economist to hold a forum
Subscribe for More Information
March 25, 2015
07:12 EDTBAXAmerican Academy of Orthopedic Surgeons to hold annual meeting
Subscribe for More Information
March 23, 2015
06:57 EDTWMTWal-Mart, Trinity church courtcase scheduled for April 8, WSJ says
A U.S. appeals court on April 8 will decide whether Wal-Mart shareholder Trinity church can force the company to hold a shareholder vote on gun sales, reports the Wall Street Journal. Wal-Mart maintains that what it chooses to sell in its stores is a matter of "regular business" and is not subject to shareholder review. Cornell law professor Lynn Stout and three dozen of her peers have submitted friend of the court briefs to support Trinity, which won an initial case against Wal-Mart in November. Reference Link
March 22, 2015
18:22 EDTWMTWal-Mart shareholders allowed to vote for independent chairman, Reuters says
Subscribe for More Information
March 19, 2015
06:28 EDTWMTWal-Mart's Walmex unit to expand more slowly this year, Reuters reports
Subscribe for More Information
March 18, 2015
09:36 EDTWMTActive equity options trading on open
Subscribe for More Information
March 16, 2015
09:15 EDTBAXCTI BioPharma shares should be bought on weakness, says Roth Capital
Subscribe for More Information
06:16 EDTWMTWal-Mart to sell Tide rival Persil in stores, WSJ reports
Subscribe for More Information
March 13, 2015
09:02 EDTBAXBaxter announces phase III trial of BAX 817 met primary endpoint
Baxter International announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa treatment for people with hemophilia A or B who develop inhibitors. The prospective, open-label, randomized, multicenter trial was designed to assess the safety and efficacy of BAX 817 in male patients ages 12 to 65 with hemophilia A or B with inhibitors over a 6-month period using on-demand therapy. The trial met its primary endpoint of successful resolution of acute bleeding episodes at 12 hours with both on-demand treatment regimens, dosing either 3x90 Ķg/kg or 1x270 Ķg/kg, with an overall success rate of 92% -- 98% and 85% in each dosing group, respectively. Further, 89% of patients in the trial achieved sustained bleeding control for all acute bleeding episodes 24 hours after infusion. No patients developed inhibitors or binding antibodies to BAX 817, and none discontinued treatment due to an adverse event. One patient was hospitalized following a traumatic muscle bleed that did not respond to BAX 817. Non-serious AEs observed in the trial were generally consistent with the underlying disease or other etiology, and were all deemed to be unrelated to treatment. Full data from the trial, including additional efficacy and safety outcomes, will be presented at a medical meeting later in 2015. The company plans to initiate regulatory submissions aligned to manufacturing expansions currently underway.
March 12, 2015
07:48 EDTWMTMcCormick downgraded at Bernstein
As noted earlier, Bernstein downgraded McCormick (MKC) to Market Perform from Outperform. The firm downgraded the stock based on the discounts that Wal-Mart (WMT) is placing on the company's 5th Season brand. Target remains $81.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use